Publications by authors named "Jaye Viner"

Claim this Profile
D
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Kaiming Sun, Ruzanna Atoyan, Mylissa A Borek, Steven Dellarocca, Maria Elena S Samson, Jaye L Viner

Mol Cancer Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Anas Younes, Jesus G Berdeja, Manish R Patel, Ian Flinn, John F Gerecitano, Jaye L Viner

Lancet Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.
Paul Haluska, Michael Menefee, Elizabeth R Plimack, Jonathan Rosenberg, Donald Northfelt, Jaye Viner

Clin Cancer Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.
Kenneth G Linden, Sancy A Leachman, Jonathan S Zager, James G Jakowatz, Jaye L Viner

Cancer Prev Res (Phila)· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered expression of insulin receptor isoforms in breast cancer.
Jiaqi Huang, Chris Morehouse, Katie Streicher, Brandon W Higgs, Jin Gao, Jaye Viner

PLoS One· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.
Jin Gao, Yong S Chang, Bahija Jallal, Jaye Viner

Cancer Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.
Anita L Sabichi, J Jack Lee, H Barton Grossman, Suyu Liu, Ellen Richmond, Jaye L Viner

Cancer Prev Res (Phila)· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Craig A Elmets, Jaye L Viner, Alice P Pentland, Wendy Cantrell, Hui-Yi Lin

J Natl Cancer Inst· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
Howard H Bailey, KyungMann Kim, Ajit K Verma, Karen Sielaff, Paul O Larson, Jaye L Viner

Cancer Prev Res (Phila)· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research.
Powel H Brown, Jaye L Viner, Abenaa Brewster, Carolyn J Heckman, Stephen Hursting

Cancer Prev Res (Phila)· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.
Martin A Cheever, James P Allison, Andrea S Ferris, Olivera J Finn, Benjamin M Hastings, Jaye L Viner

Clin Cancer Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter study of prevalence and risk factors for aberrant crypt foci.
Matthew G Mutch, Robert E Schoen, James W Fleshman, Christopher J N Rall, Sarah Dry, Jaye Viner

Clin Gastroenterol Hepatol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Translational Research Working Group developmental pathways: introduction and overview.
Ernest T Hawk, Lynn M Matrisian, William G Nelson, Gary S Dorfman, Lisa Stevens, Jaye Viner

Clin Cancer Res· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins in esophageal cancer cell lines: promising lead?
Ernest T Hawk, Jaye L Viner

Am J Gastroenterol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Scott D Solomon, Janet Wittes, Peter V Finn, Robert Fowler, Jaye Viner

Circulation· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Workshop on imaging science development for cancer prevention and preemption.
Gary J Kelloff, Daniel C Sullivan, Houston Baker, Lawrence P Clarke, Robert Nordstrom, Jaye L Viner

Cancer Biomark· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
Ernest Hawk, Jaye L Viner

Cancer Epidemiol Biomarkers Prev· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment.
Ernest Hawk, Jaye L Viner

Semin Oncol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do statins prevent cancer?
Ernest T Hawk, Jaye L Viner

Nat Clin Pract Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Celecoxib for the prevention of sporadic colorectal adenomas.
Monica M Bertagnolli, Craig J Eagle, Ann G Zauber, Mark Redston, Scott D Solomon, Jaye L Viner

N Engl J Med· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins and cancer--beyond the "one drug, one disease" model.
Ernest Hawk, Jaye L Viner

N Engl J Med· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can animal models help us select specific compounds for cancer prevention trials?
Ernest T Hawk, Asad Umar, Ronald A Lubet, Levy Kopelovich, Jaye L Viner

Recent Results Cancer Res· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The critical role of risk-benefit assessments in cancer prevention.
Ernest Hawk, Jaye L Viner

Cancer Epidemiol Biomarkers Prev· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention and therapy of colorectal cancer.
Ernest T Hawk, Asad Umar, Ellen Richmond, Jaye L Viner

Med Clin North Am· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention.
Ernest T Hawk, Jaye Viner, Ellen Richmond, Asad Umar

Cancer Chemother Biol Response Modif· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis